Author + information
- Received June 28, 2010
- Revision received October 1, 2010
- Accepted October 29, 2010
- Published online March 1, 2011.
- Morten V. Sørensen, MD⁎,
- Sune Pedersen, MD, PhD†,
- Rasmus Møgelvang, MD, PhD†,
- Jan Skov-Jensen, MD, DMSc†,‡ and
- Allan Flyvbjerg, MD, DMSc⁎,⁎ ()
- ↵⁎Reprint requests and correspondence:
Dr. Allan Flyvbjerg, Department of Endocrinology and Internal Medicine, Clinical Institute, Aarhus University Hospital, Nørrebrogade 44, DK-8000, Aarhus C, Denmark
Objectives We evaluated the potential association between plasma high-mobility group box 1 (HMGB1) levels and outcome in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention.
Background The positive effect of reperfusion after STEMI may be compromised by ischemic/reperfusion injury. HMGB1 is released by necrotic cells and, in pre-clinical studies, has been implicated to play a role in myocardial ischemic/reperfusion injury.
Methods The study included 141 STEMI patients, with acute occlusion of the left anterior descending coronary artery successfully treated with percutaneous coronary intervention. Plasma HMGB1 levels were measured by enzyme-linked immunoadsorbent assay at admission. Forty-two healthy individuals served as control subjects.
Results After a median of 10 months of follow-up, 13 STEMI patients died. There were no significant differences with regard to baseline variables between the group of patients who survived and those who died. Baseline HMGB1 levels were increased in STEMI patients when compared with control subjects. Furthermore, the STEMI patients who died had higher HMGB1 levels than those who survived. After adjusting for age, sex, troponin I, and creatine kinase-myocardial band, we found that a doubling of HMGB1 concentrations increased the risk of mortality by 75% (hazard ratio: 1.75; 95% confidence interval: 1.1 to 2.8).
Conclusions Plasma HMGB1 levels are elevated in STEMI patients compared with healthy control subjects. Furthermore, after a follow-up period of 10 months, plasma HMGB1 levels are shown to be independently associated with increased mortality in STEMI patients treated with PCI. These data suggest that plasma HMGB1 may be used as a new prognostic biomarker in STEMI patients.
- high-mobility group box 1
- ischemic/reperfusion injury
- myocardial infarction
- receptor for advanced glycation end products
This study was financially supported by the Danish Diabetes Association, the Danish Heart Foundation, the Danish Medical Research Council, and the Murermester Lauritz Peter Christensen and Wife Kirsten Sigrid Christensen Foundation. The authors have reported that they have no relationships to disclose.
- Received June 28, 2010.
- Revision received October 1, 2010.
- Accepted October 29, 2010.
- American College of Cardiology Foundation